Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer

Inclusion Criteria: * Pathologically confirmed colon adenocarcinoma (\> 15 cm from the anal verge) * Radiologic T3/T4 and high risk features by CT scan * No metastasis on CT or PET(positron emission computed tomography) * Age ≥ 18 and ≤ 70 years * ECOG (Eastern Cooperative Oncology Group) performance status 0-1 * No history of colorectal cancer within 5 years * No history of chemotherapy * Patients with childbearing potential should use effective contraception during the study and the following 6 months * Adequate bone marrow function : white blood cell count of 2 x 109/L or more with neutrophils of1.5 x 109/L or more, platelet count of 100 x 109/L or more, hemoglobin of 9 g/dL (5,6 mmol/l) or more * Adequate hepatobiliary function : total bilirubin of 0.4 mg/dl or less, ASAT (aspartate aminotransferase) and ALAT (alanine aminotransferase) of 2.5 x ULN (upper limits of normal) or less, Alkaline phosphatase of 1.5 x ULN or less * Adequate renal function : GFR (Glomerular Filtration Rate) \> 50ml/min by Wright or Cockcroft formula * Signed written informed consent obtained prior to any study specific screening procedures Exclusion Criteria: * Age \> 70 years and \< 18 years * Rectal cancer : 15 cm or less from the anal verge * Complicated colon cancer (complete obstruction, perforation, bleeding) * Metastatic colon cancer * Known hypersensitivity reaction to any of the components of study treatments * Inflammatory bowel disease * Hereditary nonpolyposis colorectal cancerHNPCC, familial Adenomatous Polyposis * Clinically relevant coronary artery disease or history of myocardial infarction in the last 6 months, high risk of uncontrolled arrhythmia * Galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption * Pregnancy or breast-feeding period * Serious non-healing wound or bone fracture * Medical, geographical, sociological, psychological or legal conditions that would not permit the patient to complete the study or sign informed consent * Any significant disease which, in the investigator's opinion, would exclude the patient from the study